- Study stopped early after review of safety and efficacy data demonstrated clear proof-of-concept and opportunity for further dose reduction to optimize clinical safety and efficacy
- Large statistically significant decreases seen for ALP in patients receiving MBX-8025; reversible dose related liver enzyme elevations observed
Slingshot members are tracking this event:
CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
May 31, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Mbx-8025, Primary Biliary Cholangitis, Pbc, Pparδ Agonist